Hikma Pharmaceuticals (HIK) AI Stock Analysis

• Market Cap: £2.66B
• Dividend Yield: 4.16%
• Average Volume (3M): 631.74K
• Price to Earnings (P/E): 11.2
• Beta (1Y): 0.90
• Revenue Growth: 3.73%
• EPS Growth: 27.13%
• Country: UK
• Employees: 9,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.56
• Shares Outstanding: 220,307,710
• 10 Day Avg. Volume: 531,484
• 30 Day Avg. Volume: 631,743
• PEG Ratio: 0.72
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 1.35
• P/FCF Ratio: 27.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £1,887.50
• Price Target Upside: 21.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 2.36
• Revenue Forecast (FY): £3.49B

• Rating: 59 Neutral
• Price Target: 1,373.00 p ▼(-11.65% Downside)
• Action: Downgraded Date: 02/28/26
• Date: Action: Downgraded 02/28/26

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

Positive Factors

High Group Profitability

A sustained ~25% group EBITDA margin indicates durable operational leverage and cost structure advantages versus peers. This level of underlying profitability supports reinvestment, R&D funding and shareholder returns, improving resilience across cycles and financing flexibility.

Rx/Generics Margin Recovery

A recovered, mid-teens to ~20% Rx margin and ~GBP200m EBIT demonstrates a structurally stronger generics franchise. Stable Rx margins provide recurring cash flow, diversify revenue away from injectables, and improve long-term margin sustainability even if other segments fluctuate.

Leading MENA & Branded Growth

Market leadership in MENA and accelerating branded growth (7–8%) create a durable commercial moat. Strong regional distribution and branded product momentum provide predictable revenue streams, pricing power in local markets, and diversification versus regulated generic markets.

Negative Factors

Weakened Cash Generation

A sharp decline in operating cash flow and a ~54% fall in free cash flow materially weakens internal funding capacity. Reduced cash conversion limits flexibility for capex, buybacks, debt reduction and acquisitions, heightening refinancing and execution risk if the trend persists.

Rising Leverage

A meaningful increase in leverage over recent years reduces financial flexibility and raises interest expense sensitivity. With higher debt levels, the company has less buffer for cyclical shocks or prolonged cash conversion weakness, which can constrain strategic investments or require prioritised deleveraging.

Injectables Structural Headwinds

The injectable franchise faces a durable margin reset plus delayed RTU launches and lost CMO volumes that postpone expected growth until new capacity is online. As injectables are a core revenue driver, these structural setbacks compress near-term margins and push out recovery timelines.

Hikma Pharmaceuticals Business Overview & Revenue Model

Company Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

How the Company Makes Money

Hikma Pharmaceuticals generates revenue through multiple key streams. The Injectables segment, which includes a range of sterile injectable products, is a significant contributor to the company's earnings, capitalizing on the rising demand for complex generics and specialty medications. The Generics segment generates income by offering a variety of generic drugs, which are typically lower-cost alternatives to branded medications. The Branded segment focuses on proprietary products in specific markets, particularly in the Middle East and North Africa, where it has established strong brand recognition. Additionally, Hikma engages in strategic partnerships and collaborations with other pharmaceutical firms, enhancing its product offerings and market reach. Factors such as regulatory approvals, market expansion strategies, and the company's ability to innovate and streamline its production processes further contribute to its overall profitability.

Hikma Pharmaceuticals Financial Statement Overview

Summary

Income statement and balance sheet are solid (steady revenue growth and recovered earnings; ROE ~16% with moderate leverage), but the latest cash flow is a key weakness: 2025 operating cash flow and free cash flow fell sharply (FCF ~-54% YoY) with weaker cash conversion versus net income.

Income Statement

Revenue has grown steadily over time (2025: +6.32% vs. 2024: ~+8.8%), showing a solid top-line trajectory. Profitability is healthy with 2025 net margin around 12% and EBIT margin around 18%, but margins have compressed versus earlier years (gross margin down from ~51–52% in 2020–2021 to ~40% in 2025). Net income has recovered from the 2022–2023 dip (2025: ~£410m vs. 2023: ~£190m), yet it remains slightly below 2020–2021 levels, suggesting improved execution but not fully back to prior peak profitability.

Balance Sheet

The balance sheet looks reasonably sound with moderate leverage: debt-to-equity is ~0.64 in 2025 (up from ~0.34 in 2021), reflecting a meaningful increase in debt over the period. Equity has grown (2025: ~£2.59bn vs. 2020: ~£2.14bn), and returns on equity are solid at ~16% in 2025, indicating the company is generating good profits relative to shareholder capital. The main watch item is the upward leverage trend, which reduces flexibility versus prior years.

Cash Flow

Cash generation weakened materially in 2025: operating cash flow fell to ~£367m from ~£564m in 2024, and free cash flow dropped to ~£165m from ~£399m (free cash flow growth ~-54%). Free cash flow is also well below net income in 2025 (about 45% of net income), pointing to weaker cash conversion this year. While the business has produced stronger cash flow in earlier years, the latest period shows volatility and a notable step-down that increases execution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.42B	3.13B	2.88B	2.52B	2.55B
Gross Profit	1.37B	1.42B	1.41B	1.26B	1.30B
EBITDA	853.54M	787.00M	791.00M	485.00M	744.00M
Net Income	410.43M	359.00M	190.00M	188.00M	421.00M
Balance Sheet
Total Assets	5.67B	5.13B	4.68B	4.47B	4.37B
Cash, Cash Equivalents and Short-Term Investments	354.13M	213.00M	229.00M	292.00M	450.00M
Total Debt	1.65B	1.31B	1.19B	1.28B	846.00M
Total Liabilities	3.07B	2.81B	2.47B	2.32B	1.91B
Stockholders Equity	2.59B	2.31B	2.20B	2.13B	2.45B
Cash Flow
Free Cash Flow	165.40M	399.00M	439.00M	392.00M	493.00M
Operating Cash Flow	366.53M	564.00M	608.00M	530.00M	638.00M
Investing Cash Flow	-402.27M	-381.00M	-333.00M	-607.00M	-238.00M
Financing Cash Flow	59.22M	-188.00M	-337.00M	-58.00M	-287.00M

Hikma Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1554.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HIK, the sentiment is Negative. The current price of 1554 is above the 20-day moving average (MA) of 1446.80, above the 50-day MA of 1509.60, and below the 200-day MA of 1717.51, indicating a bearish trend. The MACD of -99.65 indicates Positive momentum. The RSI at 21.65 is Positive, neither overbought nor oversold. The STOCH value of 1.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HIK.

Hikma Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HLN	67 Neutral	£32.63B	20.15	9.35%	1.51%	-2.12%	42.10%
VLG	65 Neutral	£84.53M	-8.91	―	―	―	―
STX	63 Neutral	£90.82M	-1.10	-396.71%	―	93.48%	51.18%
HIK	59 Neutral	£2.66B	11.21	15.83%	4.16%	3.73%	27.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AGY	45 Neutral	£728.24M	-3.26	227.10%	―	-0.28%	22.94%

Hikma Pharmaceuticals Corporate Events

Hikma launches $250m buyback with first £1.2m share purchase

Hikma Pharmaceuticals has begun executing a $250 million share repurchase programme, buying back 87,500 ordinary shares on 26 February 2026 through Citigroup Global Markets at a volume-weighted average price of 1,394.36 pence. The company plans to cancel these shares, signalling confidence in its valuation and returning excess capital to shareholders.

After this transaction, Hikma holds 12,833,233 shares in treasury and has 234,632,186 ordinary shares in issue, setting the current total voting rights at that level. The buyback and intended cancellation will gradually reduce the free float and may enhance earnings per share, with implications for the stock’s liquidity and ownership structure.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma launches $250m share buyback to bolster capital efficiency and signal growth confidence

Hikma Pharmaceuticals has launched a share buyback programme of up to $250 million in 2026, aiming to reduce its share capital while signalling strong cash generation, a robust balance sheet and board confidence in the company’s growth prospects. The programme is structured in two equal tranches of $125 million each, executed by Citigroup Global Markets and J.P. Morgan Securities as riskless principals under preset parameters and in compliance with UK market abuse and listing rules.

The first tranche will run from 26 February 2026 to no later than 9 June 2026 across several European trading venues, with the second tranche starting automatically afterwards and lasting up to three months and 10 trading days. The buyback is calibrated to maintain balance sheet efficiency while preserving headroom for organic and inorganic investment, with all repurchased shares to be cancelled or held in treasury and the continuation of the programme contingent on renewed shareholder authorities and Takeover Code waivers at the 2026 AGM.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma posts revenue growth, launches $250m buyback and overhauls leadership

Hikma Pharmaceuticals reported 2025 core revenue up 6% to $3.35 billion and core operating profit up 3% to $741 million, driven by double-digit growth in its Branded unit and solid performance in injectables and Hikma Rx across North America, MENA and Europe. Despite a drop in reported operating profit due to legal settlements and some margin pressure in Injectables, the group maintained a robust balance sheet, raised its dividend 5% and launched 84 products including its first US biosimilar.

The company announced a $250 million share buyback for 2026 and outlined modest group revenue and profit growth targets, while withdrawing previous medium-term guidance following a strategic review of its Injectables business. A sweeping leadership reshuffle will see Executive Chairman Said Darwazah focus solely on the CEO role, a new chair appointed, regional deputy CEOs created and an acting CFO installed, signalling a push for greater agility and accountability as Hikma seeks to strengthen long-term performance and capitalise on biosimilar and specialty injectables opportunities.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma Sets Date for 2025 Full-Year Results Announcement

Hikma Pharmaceuticals has scheduled the release of its financial results for the year ended 31 December 2025 on 26 February 2026, providing investors and analysts with an upcoming view of the company’s recent performance. The group will make a recorded results presentation and slide deck available on its website from 7:00am GMT and will host a live Q&A call for analysts at 9:30am GMT, underlining its continuing emphasis on transparency and engagement with the financial community.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma Executive Vice Chairman Buys £1.5m of Company Shares

Hikma Pharmaceuticals has disclosed that Executive Vice Chairman Mazen Darwazah purchased 100,000 ordinary shares in the company on 19 December 2025 on the London Stock Exchange, at a price of £14.986 per share, for a total consideration of approximately £1.5 million. The insider share purchase, reported under EU-market abuse regulations, may be interpreted by investors as a signal of confidence from senior leadership in Hikma’s prospects and valuation, potentially supporting market sentiment around the stock.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma directors restructure pledges over 2.5 million shares via Darhold Limited

Hikma Pharmaceuticals has disclosed a series of share-related transactions involving its senior leadership and a closely associated entity, Darhold Limited, in line with market abuse regulations. On 19 December 2025, Darhold released a pledge over 2.5 million Hikma ordinary shares previously in favour of Bank Julius Baer and, on the same day, granted a new pledge over the same number of shares in favour of Europe Arab Bank, with identical transactions reported in relation to Executive Chairman and CEO Said Darwazah, Executive Vice Chairman Mazen Darwazah and non-executive director Ali Al‑Husry. The moves, which were executed at a reported price of zero, indicate a refinancing or reorganisation of security arrangements over a substantial block of insider-linked shares, but do not change the overall number of Hikma shares in issue, and are therefore more relevant to understanding the directors’ personal financing structures and governance transparency than to the company’s immediate capital position.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma Pharmaceuticals Announces Share Pledge Transactions by Key Executives

Hikma Pharmaceuticals announced transactions involving the release and grant of pledges over 1,000,000 ordinary shares by Darhold Limited, a company closely associated with Hikma’s executive leadership. These transactions, involving prominent figures such as the Executive Chairman and CEO, Executive Vice Chairman, and a Non-Executive Director, were conducted in Amman, Jordan, and are part of regulatory compliance under the EU Market Abuse Regulation. The financial implications of these transactions are neutral, as the shares were pledged at a price of £0.00, indicating no immediate financial impact on the company’s operations or market positioning.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Hikma Pharmaceuticals Announces Leadership Changes and Board Appointment

Hikma Pharmaceuticals announced a leadership change with CEO Riad Mishlawi stepping down, and Executive Chairman Said Darwazah assuming CEO responsibilities. Khalid Nabilsi, the CFO, joins the Board to enhance strategic focus. The Board is confident in future growth under Said’s leadership, and a new CEO search will commence. The company’s 2025 guidance remains unchanged, with full-year results expected in February 2026.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.